24 Mar Launch of CE-Mark test to detect multiple COVID-19 variants of concern

Posted at 07:02h in Board, Novacyt Group, Products by

SNPsig® VariPLEX™ is able to detect six key mutations of SARS-CoV-2 using PCR genotyping in under two hours

Paris, France and Camberley, UK – 24 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2 February 2021, the Company will  launch SNPsig® VariPLEX™ this week as a CE-Mark approved polymerase chain reaction (PCR) assay panel able to detect the four COVID-19 variants of concern (VOC) that are currently recognised and the two most biologically significant mutations in a single kit.

https://novacyt.com/wp-content/uploads/2021/03/Novacyt-SNPsig-VariPLEX-ENGLISH-24.03.2021.pdf